Associate Professors Clare Stirzaker and David Croucher

Clare_Stirzaker_and_David_Croucher_Garvan_Institute.jpg

Cancer Council NSW grants will support innovative approaches to monitoring breast cancer recurrence and improving treatment effectiveness for high-risk neuroblastoma.

Breast cancer blood test and childhood cancer projects given the green light

Ira_Deveson_Garvan_Institute

A major new Garvan-led research project will develop advanced DNA analysis methods to provide a more detailed picture of the human genome, improving access to the benefits of genetic medicine for diverse populations.

Research to unlock life-changing benefits from advanced DNA analysis

Ira_Deveson_Garvan_Institute-2.jpg

Dr Ira Deveson will receive the Ruth Stephens Gani Medal at the 2025 Science at the Shine Dome event, in recognition of his contributions to clinical genomics and bioinformatics. 

Australian Academy of Science honours Garvan genomics researcher

Maté Biro Garvan Institute.jpg

Associate Professor Maté Biro brings specialised expertise in how immune cells interact with tumours to the Institute’s Cancer Ecosystems Program.


Garvan appoints leading expert in cancer-immune interactions

Associate Professors Owen Siggs and Jodie Ingles are leading the Genomics of Rare Disease Registry

Jodie_Ingles_and_Owen_Siggs_Garvan_Institute-2.jpg

Sydney researchers are recruiting for a study aimed at improving diagnosis, treatment and support for an estimated two million people who live with rare genetic diseases in Australia alone.

Recruiting now: study to uncover genetic cause of rare diseases

Sophie Hespe
and Associate Professor Jodie Ingles

Jodie_Sophie_Garvan-Institute.jpg

Garvan researchers update guidelines on which genes should – and which should not – be included in genetic testing for patients with hypertrophic cardiomyopathy.

Researchers refine genetic test panel for inherited cardiomyopathy

Dr-Shona-Ritchie_Garvan-Institute.jpg

Dr Shona Ritchie has received Cancer Institute NSW funding to explore how a cholesterol-regulating medication could make existing chemotherapies more effective against pancreatic cancer.

Garvan researcher to investigate cholesterol-lowering drug for pancreatic cancer treatment

221020_Katherine-Samaras_Garvan-Institute

A commonly used treatment for diabetes may hold the key to slowing cognitive decline to prevent dementia. This Phase 3 clinical trial is seeking participants.

Clinical trial will test drug treatment for prevention of dementia

Professor Paul Timpson, Dr Cecilia Chambers and Dr David Herrmann

Professor-Paul-Timpson_Dr-Cecilia-Chambers_Dr-David-Herrmann_Garvan-Institute.jpg

Scientists identify a molecule that fuels pancreatic cancer spread to the liver, opening new avenues for treatment.

A metabolism switch that could help stop the spread of pancreatic cancer

Dr Brooke Pereira with her Excellency the Honourable Ms Sam Mostyn AC at the Fulbright Gala

Brooke-Pereira-Fulbright-Gala-Garvan-Institute.jpg

Garvan’s Dr Brooke Pereira has been awarded the prestigious Fulbright Scholarship to embark on an exchange to the US, where she will investigate new therapy targets for pancreatic cancer.

Dr Brooke Pereira awarded Fulbright Scholarship

Clockwise from top left: Dr Kylie James, Dr Curtis Cai, Dr Ruebena Dawes, Dr Etienne Masle-Farquhar and Dr Drew Neavin

Kylie-James-Curtis-Cai-Ruebena-Dawes-Etienne-Masle-Farquhar-Drew-Neavin-v3.jpg

National Health and Medical Research Council backs five Garvan scientists to pursue solutions for complex diseases affecting millions of Australians.

Next wave of medical research backed by national grants

Seyhan-Yazar-Garvan-Institute

A new Garvan study will investigate how to spot multiple sclerosis before symptoms appear, to help prevent long-term nerve damage.

New research to target hidden signs of MS

Dr Alexandra Butters and Associate Professor Jodie Ingles 

jodei-and-alex-composite-v2.jpg

A case report of a misclassified cardiomyopathy gene variant highlights the need for more diversity in genomics.

Australian researchers call for greater diversity in genomics

Ankur-Sharma-Garvan-Institute

An international research project has been greenlit under the NHMRC ASPIRE program, bringing together Australian and Japanese experts to create a detailed spatial map of cancer and its immune environment.

Major Australia-Japan cancer mapping project to guide precision medicine

Cindy-Ma-Geetha-Rao-Garvan-Institute

Study of an immune messenger offers fresh hope for patients with allergies, asthma and other immune disorders.

Immune ‘mystery molecule’ points to potential targets for allergies and other immune conditions

Chris-Goodnow-Garvan-Institute

Landmark discoveries about the immune system’s protective mechanisms earn global recognition for Garvan researcher.

Professor Christopher Goodnow awarded prestigious Crafoord Prize

Professor Chris Goodnow, Dr Clara Young and Dr Dan Suan

Chris-Goodnow-Clara-Young-Dan-Suan-Garvan-Institute.jpg

Garvan researchers have uncovered how chronic hepatitis C infection leads to autoimmune disease, which opens new paths for treatments.

‘Perfect storm’ of mutations drives infection-triggered autoimmune disease

Clockwise from left: Dr Drew Neavin, Dr Brooke Pereira, Dr Andre Reis, Dr Kendelle Murphy, Dr Marcia Munoz and Professor Daniel Christ

_NHMRC-Ideas-and-Development-Grants_banner.jpg

Six research teams at Garvan have been awarded significant funding to pursue solutions across antibody therapy, inflammatory bowel disease, pancreatic cancer, bipolar disorder and genomic medicine.

Garvan research boosted by NHMRC Ideas and Development Grants

kimberley-bracelet1680x1120.png

In August, we celebrate a significant milestone with Paspaley reaching $2 million in donations in support of Garvan’s cancer research. 

Paspaley’s jewellery with purpose

antibody-illustration-Garvan-Institute

New insights into how checkpoint inhibitors affect the immune system could improve cancer treatment.

Study reveals cause of common cancer immunotherapy side effect

Brooke_Pereira_Kendelle_Murphy_Garvan_Institute

The projects are targeting the dense scarring around pancreatic tumours that hinders the success of chemotherapy.

Pancreatic cancer projects funded at Garvan to investigate new strategies for therapy

Professor Stuart Tangye and Dr Ira Deveson

Stuart-Tangye-Ira-Deveson-Garvan-Institute

Professor Stuart Tangye and Dr Ira Deveson have been recognised for their outstanding contributions to immunology and clinical genomics.

Garvan researchers honoured with NSW Premier’s Prizes

Professor-Stuart-Tangye-3_Garvan-Institute.jpg

Professor Stuart Tangye’s work advancing rare immune disease research has received national recognition.

Garvan immunologist awarded 2024 Eureka Prize

Professor Daniel MacArthur speaking at SXSW Sydney

SXSW_Daniel_MacArthur_Garvan-Institute.jpg

Researchers aim to collect genetic data from 10,000 diverse Australians to improve disease prediction, diagnosis and treatment for people from under-represented backgrounds.

Diverse Australians invited to shape future of genomic medicine

Dr David Herrmann and Professor Paul Timpson

Paul-Timpson-and-David-Hermann_Garvan-Institute.jpg

A new trial will test whether ‘priming’ pancreatic cancer can make it more susceptible to chemotherapy.

Pancreatic cancer clinical trial to test new approach to treatment

Peter_Croucher_Garvan_Institute

Professor Peter Croucher has been honoured with an award from the American Society for Bone and Mineral Research.

Prestigious bone research award for Professor Peter Croucher

190618_Alex-Swarbrick_Garvan-Institute

Research into predictive biomarkers at Garvan has been recognised internationally with a significant funding boost.

International fellowship for Garvan breast cancer researcher

Liz-Caldon-Garvan-Institute

By analysing more than 80 clinical trials, researchers at Garvan have identified genetic tests that predict which cancer patients are likely to benefit from PARP inhibitors in combination with chemotherapy.

Predicting cancer patient response to PARP inhibitors

Deborah_Burnett_Garvan_Institute

Prestigious fellowship recognises Dr Burnett’s exceptional research in immunology.

L’Oréal-UNESCO Fellowship awarded to Garvan’s Dr Deborah Burnett

Deborah-Burnett.jpg

The 2023 NSW Premier’s Prize for Early Career Researcher of the Year (Biological Sciences) recognises Garvan’s Dr Deborah Burnett.

Dr Deborah Burnett honoured with NSW Premier’s Prize

Professor Paul Timpson and Associate Professor Marina Pajic at the Garvan Institute

Paul-Timpson-Marina-Pajic-Garvan-Institute

Garvan researchers will contribute to multi-institutional collaborations to overcome current challenges in cancer treatment.

Researchers unite for major national cancer projects

Scott_Perkins_Garvan_Chair_Board.jpg

We are pleased to announce the appointment of Mr Scott Perkins as Chair of Garvan's Board of Directors. 

New Chair for Garvan Institute of Medical Research

Ira_Deveson_and_Andre_Reis_Garvan_Institute

New research provides the most comprehensive picture to date of the genomic diversity within and between First Nations communities across Australia.

Unique diversity of Indigenous Australians revealed by next-generation genomics

Dr Joanna Achinger-Kawecka and Dr David Herrmann

Joanna-Achinger-Kawecka_David Herrmann

Garvan researchers investigating the ‘ecosystems’ of breast and pancreatic cancer have been awarded Ideas Grants from the National Health and Medical Research Council.

Innovative cancer research projects awarded NHMRC funding

Professor Susan Clark, Professor Tri Phan, Associate Professor Elissa Deenick and Associate Professor Marina Pajic

Elissa-Deenick-Marina-Pajic-Susan-Clark-Tri-Phan

A significant funding boost will help Garvan’s cancer and immunology researchers pursue new directions and form collaborations.

Personalised medicine research projects backed by major grants

Professor Tri Phan, Dr Jennifer Massey and Associate Professor Elissa Deenick, leaders of the OCCAMS multiple sclerosis research consortium.

Tri-Phan_Jennifer-Massey_Elissa-Deenick_OCCAMS

Researchers and clinicians across Australia unite to develop better ways to detect, prevent and treat multiple sclerosis.

Sydney researchers to lead multiple sclerosis study

Dr Joanna Achinger-Kawecka, Professor Susan Clark and Associate Professor Clare Stirzaker

Composite_photo_.png

Garvan researchers have revealed a reason why endocrine resistance develops in breast cancers and how to potentially treat it in patients.

Epigenetic therapy shows promise for endocrine-resistant breast cancer

Professor Christopher Goodnow and Dr Tim Peters

immunity-break-story_Garvan-Institute-2.jpg

Researchers have identified a new genomic signature that controls whether the immune system’s specialised ‘killer’ T cells activate or stand down, revealing 100 potential new drug targets for cancer and autoimmune disease.

Immune ‘brake’ reveals drug targets for cancer and autoimmune disease

Dr Brooke Pereira (L) and Dr Kendelle Murphy (R)

Brooke-Pereira-and-Kendelle-Murphy_Garvan-Institute.jpeg

CINSW awards Early Career Fellowships to two Garvan cancer researchers.

Cancer Institute NSW funds early career research

220104_Thomas-Cox_Garvan-Institute

Garvan’s Associate Professor Thomas Cox has received funding to investigate a new treatment approach for pancreatic cancer.

A/Prof Thomas Cox awarded NHMRC Development Grant

Professor Mike Rogers and Dr Marcia Munoz

Mike-Rogers-and-Marcia-Munoz_Garvan-Institute.jpeg

Researchers have uncovered a mechanism by which bisphosphonates – a treatment commonly prescribed for osteoporosis – may help fight respiratory infections.

Common osteoporosis medication boosts immune response in lungs

Dr Deborah Burnett at the Garvan Institute

deborah-burnett_Garvan-Institute.jpeg

Dr Deborah Burnett outlines the pros and cons of variant-specific vaccines and the search for a universal COVID vaccine.

Will an Omicron-specific vaccine help control COVID? There’s one key problem

220128_Alex-Swarbrick_Garvan-Institute

Researchers at Garvan have identified a potential therapy that may improve how effectively chemotherapy targets neuroblastomas.

Research reveals approach to improve therapy for childhood cancer

Professor Leslie Burnett AM was among those recognised in the 2022 Australia Day Honours


220131_Leslie-Burnett-AM-Australia-Day-Honours_Garvan-Institute

For significant contributions to science, leadership, philanthropy and the arts.

Garvan community recognised in Australia Day Honours List

Dr Brooke Pereira and Professor Paul Timpson

brooke-Pereira-and-Paul-Timpson_Garvan-Institute.jpeg

PanKind foundation supports new study to improve immunotherapy outcomes in pancreatic cancer.

Funding boost to Garvan’s pancreatic cancer research

220303_Paul-Timpson_Garvan-Institute

A Garvan project to explore a potential new approach to treating fibrosis in breast cancer has been awarded a grant from the US Department of Defense.

US Defense Department backs breast cancer research

ira-deveson-and-kishore-kumar_Garvan-Institute.jpeg

Garvan researchers have shown how new genomic sequencing technology can reduce the 'diagnostic odyssey' experienced by people with rare neurological and neuromuscular diseases.

Single test for over 50 genetic diseases will cut diagnosis from decades to days

Associate Professor David Croucher, Dr Sharissa Latham and Professor Alex Swarbrick

David-Croucher-and-Sharissa-Latham-and-Alex-Swabrick.jpeg

Two teams at the Garvan Institute have been awarded project grants from Cancer Council NSW to explore innovative new frontiers in cancer research.

Cancer Council NSW grants for Garvan researchers

Professor David Thomas at Project Prospect launch at Garvan

220317_David-Thomas-Project-Prospect_Garvan-Institute

The Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) will establish Australia as a medical manufacturing hub: building links from research through to the clinic; creating jobs; changing lives.

$185 million investment to fast-track treatments for rare and ‘untreatable’ cancers

Professor Elgene Lim at the Garvan Institute

220318_Elgene-Lim_Garvan-Institute.jpeg

Cancer Council NSW awards Sally Crossing AM Award

Professor Elgene Lim recognised for outstanding outcomes in cancer research

(L-R) Mr José Alquicira-Hernández, Dr Seyhan Yazar and Professor Joseph Powell

220408_Jose-Alquicira-Hernandez-Seyhan-Yazar-Joseph-Powell_Garvan-Institute

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

An immune ‘fingerprint’ reveals path for better treatment of autoimmune diseases

220421_Stuart-Tangye_Garvan-Institute

Identifying a rare genetic mutation that weakens the immune system can better inform those who may be at higher risk of severe viral illness.

Rare genetic mutation linked to risk of severe viral infection in Polynesian populations

220509_Chris-Goodnow_Garvan-Institute

The American Association of Immunologists has awarded Professor Goodnow with the AAI-BioLegend Herzenberg Award

Professor Chris Goodnow, Garvan’s Executive Director, recognised for his outstanding work in immunology

Associate Professor Christine Chaffer and Dr Tatyana Chtanova

Christine-Chaffer-and-Tatyana-Chtanova_Garvan-Institute.jpeg

More than $1.8 million has been awarded to Garvan researchers to fund projects for breast cancer and immune system modelling.

Garvan projects funded for next stages

Professor Tri Phan at the Garvan Institute

9mb-Tri-Phan_Garvan-Institute.jpeg

A new study shows that people can increase their chances of a diagnosis by 10 per cent if they have a follow-up analysis of their genetic test

Follow-up genetic testing gives patients further chance of diagnosis

Joseph-Powell_new.png

Australian researchers uncover hidden genetic markers of glaucoma

Stem-cell models reveal glaucoma secrets

220610_Kate-Patterson_Garvan-Institute.jpeg

Research into visual scientific communication offers new insights into how to design the best visual aids to help teachers teach science.

Refining the teaching tools by creating better scientific animations

220621_Christine-Chaffer_Garvan-Institute.jpeg

Researchers are recruiting volunteers for a clinical trial they hope will improve survival rates for an aggressive form of breast cancer that affects about 1,500 women each year in New South Wales.

Explore our research

Our impact

Our people

News and resources

About us

Support Us

News

Featured Article

Recruiting now: study to uncover genetic cause of rare diseases